Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00776490 · ClinicalTrials.gov registry record · NA

Bioequivalence Study of Glimepiride 1mg Tablets Under Fasting Conditions

A NA study, sponsored by Ranbaxy Laboratories Limited.

Completed
Registry status
NA
Development phase
32
Enrollment target

NCT00776490: Completed NA study, sponsored by Ranbaxy Laboratories Limited.

NCT00776490 is a NA study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00776490, a NA study, has completed, sponsored by Ranbaxy Laboratories Limited.

COMPLETED
Registry status
NA
Development phase
32 participants
Enrollment target

Study Summary

The objective of this study is to compare the relative bioavailability of glimepiride 1 mg tablets (manufactured by Ranbaxy Laboratories Limited) with that of AMARYL® 1 mg tablets following a single oral dose (1 x 1 mg tablet) in healthy, adult subjects under fasting conditions.

Interventions

  • DRUG Glimepiride 1mg Tablets

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2003-07
Est. Completion 2003-09
Phase NA
Ranbaxy Laboratories Limited

44 total trials

What the finished NCT00776490 record still lists

NCT00776490 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Glimepiride 1mg Tablets is the first listed.

NCT00776490 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00776490 about?

NCT00776490 is a clinical study titled "Bioequivalence Study of Glimepiride 1mg Tablets Under Fasting Conditions". The objective of this study is to compare the relative bioavailability of glimepiride 1 mg tablets (manufactured by Ranbaxy Laboratories Limited) with that of AMARYL® 1 mg tablets following a single oral dose (1 x 1 mg tablet) in healthy, adult subjects under fasting conditions.

What is the current status of trial NCT00776490?

This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2003-07. Estimated completion is 2003-09.

What interventions are being tested in trial NCT00776490?

The interventions under investigation include: Glimepiride 1mg Tablets (DRUG).

Who is sponsoring clinical trial NCT00776490?

This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00776490's enrollment target sits among peer trials

32 1578th of 2000 higher than 409 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00776490, the US trial registry maintained by the National Library of Medicine. NCT00776490 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.